跳到正文
原文
MedPage Today·· 15 天前精选AI 评分66

‘永久化学物质’与雌激素受体阴性乳腺癌风险增加相关

'Forever Chemicals' Linked to Aggressive Breast Cancers

AI 导读

一项前瞻性病例-队列研究发现,两种常见的‘永久化学物质’与雌激素受体阴性乳腺癌风险增加相关。meta分析进一步支持了这一关联。研究团队认为这些发现对公共卫生有重要意义,建议减少暴露于这些化学物质的来源。

推荐理由

研究发现特定‘永久化学物质’与雌激素受体阴性乳腺癌风险增加相关,提示公共卫生需关注这些物质的长期影响。

正文 · 原文

— Findings have "important public health implications," researchers say

November 5, 2026 • 3 min read

  • A prospective case-cohort study suggested that two common per- and polyfluoroalkyl substances (PFAS) were associated with a higher risk of estrogen receptor-negative breast cancer.
  • A meta-analysis of seven studies further supported an association for perfluoro-n-octanoic acid, and less so for perfluorooctane-1-sulfonic acid.
  • Even though the compounds assessed in this study have been phased out from industry and largely replaced by other PFAS compounds, these findings have important public health implications, researchers said.

Two common "forever chemicals" were associated with a higher risk of estrogen receptor (ER)-negative breast cancer, a prospective case-cohort study suggested.

The highest exposure quartile of perfluoro-n-octanoic acid (PFOA) was associated with a higher risk of ER-negative breast cancer compared with the lowest quartile (HR 1.67, 95% CI 1.10-2.53), and the same was true for perfluorooctane-1-sulfonic acid (PFOS; HR 1.93, 95% CI 1.15-3.22), reported Alexandra J. White, PhD, of the National Institute of Environmental Health Sciences, and colleagues.

A meta-analysis of seven studies further supported an association for PFOA (relative risk [RR] 1.30, 95% CI 1.05-1.62), and less so for PFOS (RR 1.20, 95% CI 0.91-1.58), they noted in the Journal of Clinical Oncology.

"Our positive findings were generally concentrated among hormone receptor-negative tumors," White and team wrote, adding that this suggests that per- and polyfluoroalkyl substances (PFAS) "may act through nonhormonal mechanisms, consistent with the evidence that many PFAS are only weak endocrine disrupting chemicals and that other relevant mechanisms, such as epigenetic alterations and immunosuppression, may underlie these associations."

"These findings have important public health implications given the limited established risk factors for ER-negative tumors, which are generally more aggressive," they concluded.

White told MedPage Today that "there are a lot of factors related to a woman's risk of developing breast cancer. Our findings suggest these chemicals may be one contributor to ER-negative breast cancer risk specifically, and if women have concerns about their PFAS exposure, reducing exposure to sources such as contaminated water would be a very reasonable step."

She pointed out that the compounds assessed here "have been phased out from industry and largely replaced by other PFAS compounds. Most of us still have measurable levels of these compounds in our bodies and it is important to document the different health outcomes or cancer tumor sites that are related to exposure to these compounds."

"From a public health perspective, we probably want to start shifting our focus to the health effects of these replacement PFAS compounds that are being used more today," she added.

There have been several other studies that have demonstrated positive associations between PFOS and PFOA and ER-negative tumors, including an analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial and a French study.

For this analysis, the authors used the Sister Study, a prospective cohort of 50,884 breast cancer-free women ages 35 to 74, each of whom had a full or half-sister diagnosed with breast cancer, enrolled in the U.S. and Puerto Rico between 2003 and 2009.

The researchers included 1,609 women who developed breast cancer and a comparison sample of 2,269 women. They were followed for a median of 5.9 and 9.7 years, and had a median baseline age of 57.2 and 55.6 years, respectively.

White observed that she and her team oversampled women with ER-negative tumors to improve the study's statistical power. "These tumors are less frequently diagnosed and so they've been harder to study," she said.

White and her team quantified 17 PFAS in prediagnostic plasma using liquid chromatography-high-resolution mass spectrometry.

They also observed a potential link between n-methylperfluoro-1-octanesulfonamidoacetic acid and ER-negative breast cancer, although that association did not reach statistical significance (HR 1.42, 95% CI 0.99-2.04).

On the other hand, perfluoro-n-tridecanoic acid was inversely associated with ER-negative tumors (HR 0.63, 95% CI 0.41-0.97).

Perfluorooctane sulfonamide (PFOSA), which was not commonly detected (6.9%), was positively associated with ER-positive tumors (HR 1.36, 95% CI 1.03-1.81).

Regarding overall breast cancer incidence, White and colleagues found that PFOSA showed a trend toward higher risk among patients with detectable versus non-detectable concentrations (HR 1.29, 95% CI 0.99-1.67), while perfluoro-n-decanoic acid showed a "suggestive" positive association (HR 1.17, 95% CI 0.95-1.44).

There were "negligible" associations between the rest of the PFAS and overall breast cancer incidence.

来源:MedPage Today · medpagetoday.com